Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion

Reuters

11/13

<a href="https://laohu8.com/S/MKGAF">Merck KGaA</a> third-quarter net sales rise 1.0% to €5.3 billion

Merck KGaA reported net sales of €5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to €1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism & Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks Therapeutics contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583530615"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583530615\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583530615?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 14:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583530615","market":"us","top_or_hot":-1,"title":"Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> third-quarter net sales rise 1.0% to €5.3 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> reported net sales of €5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to €1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism &amp; Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck KGaA third-quarter net sales rise 1.0% to €5.3 billion\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-13 14:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> third-quarter net sales rise 1.0% to €5.3 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> reported net sales of €5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to €1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism &amp; Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7ztz5W:1","article_id":"2583530615","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583530615","pubTimestamp":1763013678,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Merck KGaA reported net sales of 5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to 1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism & Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks Therapeutics contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SWTX":"SpringWorks Therapeutics, Inc."},"translate_title":"默克集团第三季度净销售额增长1.0%至53亿欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SWTX":0.9},"content_text":"Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion\n    \n\nMerck KGaA reported net sales of €5.3 billion for the third quarter of 2025, reflecting organic growth of 5.2%. Foreign exchange effects reduced net sales by 4.9%, while portfolio effects added 0.7%. EBITDA pre increased organically by 8.8% to €1.7 billion, with foreign exchange effects of -6.5% and portfolio effects of +0.9%. Growth was mainly driven by the Process Solutions segment in Life Science, Rare Diseases in Healthcare, and Semiconductor Solutions in Electronics. The Healthcare sector saw organic sales growth of 4.6%, supported by strong performance in Cardiovascular, Metabolism & Endocrinology and sales of Mavenclad and Erbitux. The acquisition of SpringWorks Therapeutics contributed to positive portfolio effects, establishing Rare Diseases as a new strategic focus. Merck KGaA confirmed its guidance for the full year 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}